VivoSeq
Metabolic & Endocrine

Hyperaldosteronism

7

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

Hyperaldosteronism is an early-stage landscape with 7 programs across 4 companies. The most active players are Novartis, AstraZeneca, Eli Lilly. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Pfizer logo

Pfizer

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

7

clinical trials

Completed3 · 43%
Recruiting3 · 43%
Withdrawn1 · 14%

Clinical Trials

Trial Activity

7 trials

Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism
Recruiting·—·N/A·NCT07328230·172 enrolled
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT07007793·250 enrolled
Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06246357·80 enrolled
Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Completed·UUniversity of Alabama at Birmingham·N/A·NCT01897727·41 enrolled
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
Completed·Novartis logoNovartis·Phase 2·NCT00732771·12 enrolled
Tissue K+ in Primary Hyperaldosteronism
Completed·UUniversity of Erlangen-Nürnberg Medical School·N/A·NCT04251780·21 enrolled
Investigating Salt Taste Threshold in Patients Being Investigated for Primary Hyperaldosteronism Before and After Treatment.
Withdrawn·IImperial College London·N/A·NCT04556279

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)